Gilead Sciences will expand its data reporting requirements for 340B pricing on branded hepatitis C products to contract pharmacies wholly owned by covered entities.

Gilead Expands 340B Reporting to Wholly Owned Contract Pharmacies

January 3, 2024 Rich Daly Editor in Chief Views

Drugmaker Gilead Sciences will expand its data reporting requirements for 340B pricing on branded hepatitis C products to contract pharmacies [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Gilead Expands 340B Reporting to Wholly Owned Contract Pharmacies

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Rich Daly